Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedJun 25, 2026
DataAggregated Company Financials
Companies9
  • 7D2.4%
  • 3M6.7%
  • 1Y32.7%
  • YTD8.5%

The Pharma industry is up 2.4% in the last week, with Novartis up 2.8%. During this same period, the Dottikon ES Holding underperformed, falling 5.2%. This means that the industry has gained 33% over the past year. Looking forward, earnings are forecast to grow by 10% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 25 Jun 2026CHF 572.1bCHF 123.2bCHF 25.2b37.6x22.7x4.6x
Sat, 23 May 2026CHF 566.3bCHF 121.2bCHF 24.8b38.9x22.8x4.7x
Mon, 20 Apr 2026CHF 555.2bCHF 121.0bCHF 25.1b40.1x22.1x4.6x
Wed, 18 Mar 2026CHF 557.6bCHF 121.3bCHF 25.2b37.9x22.2x4.6x
Fri, 13 Feb 2026CHF 594.6bCHF 119.3bCHF 24.3b36.1x24.5x5x
Sun, 11 Jan 2026CHF 582.1bCHF 121.5bCHF 21.6b36.2x27x4.8x
Tue, 09 Dec 2025CHF 547.4bCHF 122.0bCHF 21.7b34.5x25.2x4.5x
Thu, 06 Nov 2025CHF 485.8bCHF 122.1bCHF 21.7b32.1x22.4x4x
Sat, 04 Oct 2025CHF 508.8bCHF 120.1bCHF 20.9b33.5x24.3x4.2x
Mon, 01 Sep 2025CHF 479.3bCHF 120.4bCHF 21.0b30.4x22.9x4x
Wed, 30 Jul 2025CHF 463.2bCHF 120.7bCHF 20.9b23.4x22.2x3.8x
Fri, 27 Jun 2025CHF 449.3bCHF 117.5bCHF 19.0b25.2x23.7x3.8x
Sun, 25 May 2025CHF 436.0bCHF 118.8bCHF 19.2b25x22.7x3.7x
Tue, 22 Apr 2025CHF 413.0bCHF 117.3bCHF 18.4b24.6x22.4x3.5x
Thu, 20 Mar 2025CHF 482.1bCHF 121.3bCHF 19.1b29.4x25.2x4x
Sat, 15 Feb 2025CHF 475.3bCHF 122.3bCHF 19.1b22.9x24.9x3.9x
Mon, 13 Jan 2025CHF 444.2bCHF 120.1bCHF 21.5b18.5x20.7x3.7x
Wed, 11 Dec 2024CHF 423.4bCHF 117.9bCHF 21.1b18.1x20x3.6x
Fri, 08 Nov 2024CHF 441.0bCHF 117.2bCHF 21.0b19x21x3.8x
Sun, 06 Oct 2024CHF 445.7bCHF 115.4bCHF 19.4b21.1x23x3.9x
Tue, 03 Sep 2024CHF 479.4bCHF 115.0bCHF 19.3b22.9x24.8x4.2x
Thu, 01 Aug 2024CHF 467.4bCHF 116.5bCHF 19.7b22.6x23.8x4x
Sat, 29 Jun 2024CHF 434.0bCHF 116.4bCHF 19.8b33.7x21.9x3.7x
Mon, 27 May 2024CHF 409.2bCHF 117.4bCHF 19.9b42.1x20.5x3.5x
Wed, 24 Apr 2024CHF 400.2bCHF 113.5bCHF 20.0b37x20.1x3.5x
Fri, 22 Mar 2024CHF 386.7bCHF 111.7bCHF 19.4b37.9x20x3.5x
Sun, 18 Feb 2024CHF 380.8bCHF 110.4bCHF 19.7b23.9x19.3x3.4x
Tue, 16 Jan 2024CHF 415.7bCHF 119.6bCHF 18.7b27.1x22.2x3.5x
Thu, 14 Dec 2023CHF 405.6bCHF 120.9bCHF 18.9b25x21.5x3.4x
Sat, 11 Nov 2023CHF 385.0bCHF 122.7bCHF 19.1b23.4x20.2x3.1x
Mon, 09 Oct 2023CHF 405.3bCHF 122.0bCHF 18.7b26.3x21.7x3.3x
Wed, 06 Sep 2023CHF 398.0bCHF 112.2bCHF 18.0b47.4x22.1x3.5x
Fri, 04 Aug 2023CHF 410.7bCHF 114.8bCHF 19.3b48.1x21.3x3.6x
Sun, 02 Jul 2023CHF 421.0bCHF 115.1bCHF 18.9b36.9x22.3x3.7x
Price to Earnings Ratio

22.3x


Total Market Cap: CHF 421.0bTotal Earnings: CHF 18.9bTotal Revenue: CHF 115.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 22.5x.
  • The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 10% per year over the last three years.
  • Revenues for these companies have grown 2.3% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.84%
Healthcare2.65%
Pharma2.37%
Pharma2.37%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVN NovartisCHF 126.006.7%
+CHF 14.6b		31.2%PE21x
ROP Roche HoldingCHF 335.305.1%
+CHF 13.0b		27.9%PE20.7x
SDZ Sandoz GroupCHF 73.268.2%
+CHF 2.4b		70.6%PE42.7x
GALD Galderma GroupCHF 178.503.4%
+CHF 1.4b		55.1%PE84.1x
COPN CosmoCHF 67.000.8%
+CHF 8.1m		18.2%PS11.3x

Latest News

DESN
CHF 277.00
Dottikon ES Holding
7D
-6.4%
1Y
-6.4%
Analysis Article • Jun 24

Downgrade: Here's How Analysts See Dottikon ES Holding AG (VTX:DESN) Performing In The Near Term

Today is shaping up negative for Dottikon ES Holding AG ( VTX:DESN ) shareholders, with the analysts delivering a...
ROP
CHF 335.30
Roche Holding
7D
5.1%
1Y
27.9%
NOVN
CHF 126.00
Novartis
7D
6.7%
1Y
31.2%
COPN
CHF 67.00
Cosmo
7D
0.8%
1Y
18.2%
Narrative Update • Jun 22

COPN: European Dermatology Expansion Will Support CHF 160 Upside Potential

Analysts lifted their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple as key drivers of the change. What’s in the News for Cosmo Cosmo Pharmaceuticals N.V. reported that partners Glenmark Specialty S.A. and InfectoPharm launched Winlevi (clascoterone 1% cream) in key European markets, including Austria and Germany, following European Commission marketing authorization, according to recent company news.
SDZ
CHF 73.26
Sandoz Group
7D
8.2%
1Y
70.6%
Analysis Article • Jun 19

Sandoz Group (SWX:SDZ) Stock Could Be 2% Overvalued After Ljubljana Biosimilar Centre Launch

Sandoz Group (SWX:SDZ) has opened a new biosimilar development centre in Ljubljana, Slovenia, a fully digitally integrated US$99 million facility that expands its in house capabilities across drug substance and drug product development. See our latest analysis for Sandoz Group. Set against this investment in Ljubljana, Sandoz Group’s 1 day share price return declined 1.60% to CHF67.68, while its year to date share price return of 18.28% and 1 year total shareholder return of 57.12% suggest...
GALD
CHF 178.50
Galderma Group
7D
3.4%
1Y
55.1%
Narrative Update • Jun 17

GALD: Rising Execution Bar And Rich P/E Will Likely Cap Future Share Upside

Analysts have raised the Galderma Group price target by CHF 5 to CHF 125.65, citing updated assumptions on fair value, revenue growth, profit margins and forward P/E that are consistent with a recent series of target increases from major banks. Analyst Commentary Recent Street research on Galderma Group points to a cluster of higher price targets, framed around updated assumptions for earnings quality, revenue mix and P/E levels.
ADXN
CHF 0.045
Addex Therapeutics
7D
0.9%
1Y
-24.3%
NWRN
CHF 12.46
Newron Pharmaceuticals
7D
2.0%
1Y
86.2%
New Narrative • May 10

Still A Binary Phase III Bet on Evenamide

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.
BIOV
CHF 25.70
BioVersys
7D
-3.7%
1Y
-25.5%